Amgen Inc.
Every calculator, already run for AMGN
Open the full toolkit →You have the numbers on AMGN. Get the argument.
A written report on which of these readings actually decide the outcome for Amgen Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
33 analysts covering AMGNAnalyst Price Target Disagreement for Amgen Inc.
Wall Street's bull case implies +19% from the current price; the bear case implies -42%. A 60% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AMGN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma;…
AMGN — frequently asked
Is AMGN a buy right now?
Wall Street's consensus rating on Amgen Inc. is Hold across 33 analysts, with a mean price target of $387.69 (+1% vs. the current $385.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is AMGN overvalued?
AMGN trades at 24.0x trailing earnings, against a DCF fair value of $621 per share. The current price implies 0% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is AMGN's next earnings date?
Amgen Inc. is next scheduled to report earnings around Nov 3, 2026. A full AMGN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Amgen Inc.?
Analysts covering Amgen Inc. (AMGN) range from a bear-case target of $225.00 to a bull-case high of $457.00, with a mean consensus target of $387.69 across 29 analysts. The spread of $232.00 (60% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Amgen Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Amgen Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AMGN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Amgen Inc., in minutes. 3 free reports included with every account — no credit card required.